Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]

Authors Hodgson RE

Received 23 August 2019

Accepted for publication 23 August 2019

Published 9 September 2019 Volume 2019:11 Pages 567—568

DOI https://doi.org/10.2147/CEOR.S228414


Hodgson RE. Clinicoecon Outcomes Res. 2019;11:517–524.

On page 523, “Acknowledgments” and “Disclosure” sections should read as follows:

Acknowledgments
The author would like to thank C Aladakatti, B Davenport, and T Saravanappa for their assistance with data collection and A Kinmond for help with manuscript revision. Dr Hodgson has received lecture fees and educational support from Janssen, Lundbeck and Otsuka. Lundbeck has provided financial support for medical writing assistance provided by David Whitford and HAVAS Just. Lundbeck had no influence or input in this service evaluation and submission of manuscript.
Disclosure
The author reports no conflicts of interest in this work.

Following a review of the funding statement in the “Acknowledgments” section post-publication, "unrestricted educational grant” was mistakenly used. The author apologies for this oversight.


 
Read the original article 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]